Ibogaine was not included in the 2023 Stanford study as a footnote to the PTSD findings. The cohort of 30 special operations veterans was selected in part because they had traumatic brain injury alongside PTSD and treatment-resistant depression — conditions that tend to co-occur in this population and that conventional psychiatry has largely failed to address together. At one month: PTSD symptoms decreased 88%, depression 87%, anxiety 81%. The mechanism ibogaine triggers — primarily upregulation of glial cell line-derived neurotrophic factor (GDNF) and sustained changes in neuroplasticity — is relevant to TBI pathology in ways that most psychiatric medications are not.
The Stanford study (Nature Medicine, 2023) enrolled 30 special operations veterans with TBI, PTSD, and treatment-resistant depression. At one month post-ibogaine: 88% reduction in PTSD symptoms, 87% in depression, 81% in anxiety. The TBI-relevant mechanism involves GDNF upregulation and reduced neuroinflammation. Absolute contraindications apply regardless of TBI diagnosis. Ibogaine is not approved as a TBI treatment anywhere.
What traumatic brain injury does to the brain
TBI disrupts brain function through several overlapping mechanisms. The initial impact — whether blast exposure, direct head trauma, or repeated subconcussive hits — produces diffuse axonal injury: shearing of the long-range connections between neurons. This is followed by a secondary injury phase: neuroinflammation, excitotoxicity, oxidative stress, and disruption of the blood-brain barrier.
The longer-term picture in TBI includes chronic neuroinflammation driven by activated microglia, reduced levels of brain-derived neurotrophic factor (BDNF) and GDNF, impaired synaptic plasticity, and altered activity in circuits governing emotion regulation and executive function. These downstream effects overlap substantially with what happens in treatment-resistant PTSD and depression — which is one reason why TBI and psychiatric conditions co-occur so frequently in veterans.
This is the landscape conventional pharmacology is working against. SSRIs increase serotonin availability. They do not repair axonal connectivity, reduce chronic neuroinflammation, or restore GDNF levels. That is not a criticism of SSRIs — they are appropriate for many conditions. It is a description of the scope of the problem in chronic TBI, and why TBI-related psychiatric sequelae are so resistant to standard treatment.
What the Stanford study showed — and what it didn't
The study, published in Nature Medicine in February 2023, enrolled 30 special operations veterans. All had PTSD, traumatic brain injury, and treatment-resistant depression. All had been through conventional treatment and not achieved adequate resolution.
At one month post-ibogaine: PTSD symptoms decreased an average of 88%. Depression symptoms decreased 87%. Anxiety symptoms decreased 81%. These are not rounded figures — they are the numbers from the published data. In context: conventional antidepressant research considers a 50% reduction in depression scores a strong response. The Stanford results are nearly double that threshold.
Special operations veterans are not, as a population, people who enter things naively. They have been through programmes. They have been given diagnoses and medications. Many arrive sceptical that anything is going to work. The Stanford cohort — people who had documented TBI alongside PTSD, most with multiple deployment histories — were not choosing ibogaine as a first option. They had tried everything else first. That context is part of why the numbers matter.
Then the caveats, because honest reporting requires them. The Stanford study is important but limited — 30 veterans is not a definitive population. The absence of a placebo arm is a genuine methodological limitation. The study does not separate TBI-specific outcomes from PTSD-related outcomes: the population had both, and the measures assessed psychiatric symptoms rather than TBI biomarkers. What the study shows is that ibogaine produced substantial reductions in psychiatric sequelae in a population where TBI and PTSD co-occurred, where conventional treatment had already failed, and where the improvement at one month was substantial. Citing 88% as proof that ibogaine cures TBI would misrepresent the data. Citing it as evidence of a clinically meaningful signal that warrants further investigation — and further investigation is precisely what is now underway — is accurate.
For more on the psychiatric outcomes specifically, see the PTSD-focused overview and the detailed Stanford study breakdown.
How ibogaine's mechanism addresses TBI pathology
Ibogaine is not primarily a serotonin drug. The mechanism differs substantially from SSRIs, SNRIs, and most conventional psychiatric medications — which is one reason it produces effects in treatment-resistant populations where those medications have not.
The key documented pathway is ibogaine's effect on GDNF — glial cell line-derived neurotrophic factor. GDNF is a protein that supports the survival and function of neurons, particularly dopaminergic neurons in the midbrain. Ibogaine administration produces significant upregulation of GDNF in animal models. The upregulation is sustained after the acute ibogaine experience ends. This is relevant to TBI because TBI depresses GDNF levels, and reduced GDNF is associated with impaired neuronal repair and increased vulnerability to further neurodegeneration.
Ibogaine also acts as an NMDA receptor antagonist — blocking a glutamate receptor involved in excitotoxicity, which is one of the secondary injury mechanisms in TBI. Reduced NMDA activity decreases the excitotoxic damage that continues after the initial injury. It also demonstrates anti-inflammatory properties in animal models: reduced microglial activation and lower levels of pro-inflammatory cytokines, addressing another persistent feature of chronic TBI.
None of these mechanisms have been established in human TBI trials. Animal models and the correlative evidence from the Stanford cohort suggest the pathways are there. The clinical trials now underway are designed to establish whether and how they apply in humans. For a fuller account of the pharmacology, see how ibogaine works.
The GDNF research and what it means
GDNF has been studied as a potential treatment for Parkinson's disease — which also involves degeneration of dopaminergic neurons — and the results have been mixed. Direct delivery to the brain is technically difficult, and systemic administration doesn't cross the blood-brain barrier reliably. Ibogaine's apparent ability to increase GDNF expression without direct delivery is one reason neurologists and neuroscientists have taken an interest beyond the addiction and PTSD research.
The GDNF/ibogaine research connects to what has been observed clinically in addiction treatment: ibogaine produces reductions in craving for alcohol and opioids that persist beyond the acute experience. GDNF upregulation in the midbrain dopaminergic pathways is the mechanism most consistently cited to explain this effect. In TBI, those same pathways are disrupted. Whether ibogaine's GDNF effect translates to functional recovery in TBI patients is the question the current trials are designed to answer.
The noribogaine question is also relevant here. Noribogaine — ibogaine's primary metabolite — remains biologically active in the body for weeks to months after a single flood dose. The sustained neuroplasticity window observed in ibogaine research is associated with noribogaine's continuing activity. If part of ibogaine's mechanism in TBI involves GDNF upregulation and restoration of neuroplasticity, the weeks following the ceremony may matter as much as the ceremony itself. This is why integration support in the period after ibogaine is not optional — it is the window during which the brain is most capable of establishing new patterns.
Current clinical trials and where the research is going
Following the Stanford publication, four Texas universities — UTMB, UTHealth Houston, Texas A&M, and Baylor — committed $50 million USD to ibogaine clinical trials. These are the most significant trials currently underway. They include specific study of TBI populations and are designed to produce the controlled, larger-scale data the Stanford study could not. The UTMB programme is the lead institution.
Veterans' health organisations and VA-adjacent institutions are paying attention. The population of veterans with TBI and treatment-resistant psychiatric conditions is substantial. The cost and failure rate of conventional treatment are documented. There is institutional motivation to find what works, and the Stanford results provided a signal compelling enough to attract serious research investment.
Vancouver is not part of those clinical trials. Ibogaine ceremony here is not clinical ibogaine research — it is ceremony in the Bwiti tradition with medical screening and facilitation. If contributing to the research matters to you, the Texas trial sites are the relevant contact point. If what you are looking for is access to the medicine now, in a properly screened programme, Vancouver is where that is available in North America.
Who cannot proceed with ibogaine
A TBI diagnosis does not bypass the contraindications. The cardiac and psychiatric screening requirements apply regardless of injury history, and they disqualify a meaningful proportion of people who want to proceed.
QT prolongation on EKG or significant cardiac arrhythmiais an absolute contraindication. Ibogaine prolongs the QT interval throughout the 12–24 hour active experience. In someone with baseline QT prolongation, this creates the conditions for potentially fatal arrhythmia. The EKG identifies this before ceremony — not as a formality, but as the mechanism for ruling out the people for whom the medicine is acutely dangerous. See the full account of cardiac risk and ibogaine.
SSRIs and SNRIsare absolute contraindications. The risk is serotonin syndrome, which can be fatal. The medication must be fully tapered under physician supervision and cleared before any ceremony proceeds. Do not stop psychiatric medication on your own. Fluoxetine has a significantly longer half-life than other SSRIs and may require 4–6 weeks of clearance after the final dose.
Active psychosis or schizophrenia-spectrum disorder is an absolute contraindication, including first-degree family history of schizophrenia. Severe liver or kidney disease is an absolute contraindication. Pregnancy. Lithium and certain other psychiatric medications. Methadone requires a specific transition protocol before candidacy can be established.
The most common conversation that ends in a no involves a veteran with TBI who is also on antidepressants prescribed for the co-occurring PTSD and depression. The TBI diagnosis does not change the SSRI contraindication. The path to ceremony, if appropriate, involves a supervised taper and clearance of the medication first — a process that can take weeks and requires coordination between the prescribing physician and the programme. Some candidates complete that process and proceed. Some do not.
What a programme involves
The ceremony at Transcend involves a full ibogaine flood dose in the Bwiti tradition, lasting 12–24 hours in the active phase, followed by 2–3 days of recovery on-site. A physician is present throughout the ceremony. ECG monitoring runs continuously. Medical screening precedes any ceremony date: EKG, blood panel covering liver and kidney function, psychiatric history review, and complete medication assessment.
Cost ranges from $2,000–$5,000 CAD. The variation reflects what the individual programme requires: screening findings, group or private format, and the integration support structure that follows. Integration coaching — $150–$300 CAD per session — is the work done in the weeks after ceremony while the noribogaine window remains open. That work determines whether the neurological changes produced during ceremony become durable or temporary.
Is this right for you?
If you have TBI — alongside PTSD, depression, or on its own — and conventional treatment has not produced adequate resolution, ibogaine may be worth a serious evaluation. That evaluation begins with medical screening, not with a ceremony date. The screening determines candidacy. Many people who contact us do not proceed — not because ibogaine is wrong for them in principle, but because a contraindication makes it unsafe at this time.
If you want to understand the process before applying: ceremony overview, frequently asked questions, what integration involves. If you are ready to begin the intake process: apply here. Every application receives a personal response within 2–3 business days.
Frequently asked questions
Does ibogaine treat traumatic brain injury directly?
Not in any approved or established clinical sense. The mechanism — GDNF upregulation, NMDA antagonism, anti-inflammatory effects — is relevant to TBI pathology, and the Stanford cohort included veterans with TBI who showed substantial reductions in psychiatric symptoms. Whether ibogaine acts directly on TBI pathology, indirectly through its effects on co-occurring PTSD and depression, or both is the question the current Texas trials are designed to answer. What is established is that the medicine produced meaningful psychiatric improvements in a TBI population where conventional treatment had not.
What exactly did the Stanford study show about TBI?
The Stanford study enrolled 30 special operations veterans with PTSD, TBI, and treatment-resistant depression. At one month: PTSD symptoms reduced 88%, depression 87%, anxiety 81%. The study did not measure TBI-specific biomarkers separately — the outcomes measured were psychiatric. It established that ibogaine produces substantial psychiatric improvements in a population that had TBI alongside PTSD, not that it repairs TBI neuropathology directly. The distinction matters for accurate interpretation, and the results are significant regardless of which causal pathway is primary.
Why does GDNF matter for TBI?
GDNF — glial cell line-derived neurotrophic factor — supports the survival and repair of neurons, particularly in the dopaminergic pathways of the midbrain. TBI reduces GDNF expression, and low GDNF is associated with impaired neuronal recovery and increased vulnerability to neurodegeneration. Ibogaine upregulates GDNF in animal models, and the effect is sustained after the acute experience ends. This is the mechanism most consistently cited in relation to ibogaine's effects on addiction and neuroplasticity, and it is also the mechanism most relevant to TBI recovery.
Can someone with TBI proceed if they are on SSRIs or antidepressants?
Not without first completing a supervised taper and clearance period. SSRIs and SNRIs are absolute contraindications for ibogaine ceremony — the risk is serotonin syndrome, which can be fatal. The medication must be fully tapered under the supervision of the prescribing physician. Fluoxetine may require 4–6 weeks of clearance after the final dose due to its long half-life. No ceremony date is set until that process is complete. If you are on SSRIs prescribed for TBI-related PTSD or depression, the first step is a conversation with your prescribing physician, not a ceremony application.
Where are the current ibogaine TBI clinical trials?
The most significant ongoing trials are at four Texas institutions: UTMB, UTHealth Houston, Texas A&M, and Baylor. These trials are funded at $50 million USD and include specific study of TBI populations. They are not accessible through Transcend in Vancouver — they are research programmes. If participating in clinical research is the goal, UTMB is the lead institution. If the goal is access to ibogaine ceremony in a properly screened programme now, Vancouver is where that is available in North America.
How long do the effects last after ibogaine ceremony?
The Stanford study measured outcomes at one month — that is the published data point. Noribogaine remains biologically active for weeks to months after a single flood dose, sustaining elevated neuroplasticity throughout that window. Whether the psychiatric improvements documented at one month persist at six months or a year depends substantially on what is done during the noribogaine window: integration support, behavioural change, and addressing the environmental and relational factors that sustained the problem. The ceremony does not produce permanent change on its own. The window it opens is the mechanism.
What does ibogaine ceremony cost for TBI-related treatment?
At Transcend in Vancouver, iboga ceremony costs $2,000–$5,000 CAD. This includes an on-site physician throughout the 12–24 hour active experience, continuous cardiac ECG monitoring, whole-plant root bark, facilitation, and 2–3 days of supervised recovery. Integration coaching is $150–$300 CAD per session, 60–90 minutes. The total depends on what the individual programme requires. There is no TBI-specific pricing — the same programme applies, and candidacy is determined through screening regardless of the condition being addressed.
Is ibogaine legal in Canada for TBI treatment?
Ibogaine is not listed under Canada's Controlled Drugs and Substances Act — it is not explicitly prohibited. This places it in a legally distinct position from the United States, where ibogaine has been Schedule I since 1970. Providers in Vancouver, BC operate openly under this status. Ibogaine is not approved as a treatment for TBI or any other condition in Canada — the legal permissibility of the substance is different from regulatory approval as a medical treatment. The absence of legal prohibition is what makes access possible; the absence of approval is why the research being conducted in Texas matters.